New combo therapy aims to control advanced prostate cancer
NCT ID NCT07190300
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This study tests a new drug called tulmimetostat combined with standard hormone therapies (darolutamide or abiraterone) in men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination is safe and works better than standard care alone. About 181 men will take part, and the study is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact Email: •••••@•••••
-
Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
WITHDRAWNCamperdown, New South Wales, 2050, Australia
-
Novartis Investigative Site
RECRUITINGWollongong, New South Wales, 2500, Australia
-
Novartis Investigative Site
RECRUITINGGuangzhou, 510060, China
-
Novartis Investigative Site
RECRUITINGCréteil, 94010, France
-
Novartis Investigative Site
RECRUITINGLille, 59020, France
-
Novartis Investigative Site
RECRUITINGNantes, 44093, France
-
Novartis Investigative Site
RECRUITINGJena, Thuringia, 07740, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGHong Kong, 999077, Hong Kong
-
Novartis Investigative Site
RECRUITINGBudapest, H 1122, Hungary
-
Novartis Investigative Site
RECRUITINGBudapest, H-1083, Hungary
-
Novartis Investigative Site
RECRUITINGSzeged, 6725, Hungary
-
Novartis Investigative Site
RECRUITINGRozzano, MI, 20089, Italy
-
Novartis Investigative Site
RECRUITINGVerona, VR, 37134, Italy
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGMajadahonda, Madrid, 28222, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28040, Spain
-
Novartis Investigative Site
RECRUITINGAnkara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
-
Uni Of Iowa Hospitals And Clinics
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Email: •••••@•••••
-
Wichita Urology Group PA
RECRUITINGWichita, Kansas, 67226, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.